GRAND RAPIDS, Mich., Nov. 4, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that Rob Ball, CEO, will present at the upcoming Jefferies Global Healthcare Conference. The presentation will take place at 8:30 a.m. GMT / 3:30 a.m. EST on November 18, 2025.
Event: Jefferies Global Healthcare Conference
Date: Tuesday, November 18, 2025
Time: 8:30 a.m. GMT / 3:30 a.m. EST
A live and archived version of the fireside chat will be available on the "Investor Relations" section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/.
About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

| Last Trade: | US$15.19 |
| Daily Change: | -0.30 -1.94 |
| Daily Volume: | 13,211 |
| Market Cap: | US$481.010M |
December 03, 2025 November 11, 2025 September 22, 2025 September 09, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load